GSK GlaxoSmithKline PLC

-0.13  -0%
Previous Close 40.05
Open 39.85
Price To book 88.71
Market Cap 98163280000
Shares 2,459,000,000
Volume 3,797,151
Short Ratio 1.64
Av. Daily Volume 2,757,154

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data likely due 4Q 2017.
anti-SAP mAb
Phase 3 data due 1H 2019.
Atopic dermatitis, psoriasis
sBLA filing announced June 28, 2017.
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Phase 3 trial initiation announced June 27, 2017. To be completed in 2019.
Mepolizumab - SYNAPSE
Nasal polyps
Phase 3 trial initiation noted March 31, 2017.
Severe hypereosinophilic syndrome (HES)
Phase 3 trial commenced 4Q 2016.
Daprodustat - ASCEND-ND
Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
Dolutegravir + lamivudine (GEMINI 2)
Phase 2b data due 2H 2017.
GSK 165
Rheumatoid arthritis
sBLA filing announced March 15, 2017.
Fluarix Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 3 data due 2017.
Chronic obstructive pulmonary disease (COPD)
Primary endpoint of non inferiority met - December 19, 2016. NDA filing announced June 5, 2017. Priority review requested - estimate PDUFA December 5, 2017 (6 month timeline) assuming priority review granted.
Dolutegravir + rilpivirine:
Phase 3 METREX trial met primary endpoint. Phase 3 METREO failed to meet endpoint.
Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype
Phase 3 trial commenced August 2016. Data likely due 1Q 2018.
Dolutegravir + lamivudine (GEMINI 1)
Phase 3 data due 2H 2018.
Closed Triple - CAPTAIN
Phase 3 trial commenced 4Q 2016. Data due 2H 2020.
Daprodustat - ASCEND-D
Phase 3 commenced December 2016.
Cabotegravir long-acting
Phase 2b data due 1H 2019.
Inhaled PI3Kδ inhibitor
Chronic obstructive pulmonary disease (COPD)
Phase 2b data due 2H 2017.
GSK 166
Rheumatoid arthritis
Phase 2 data due 2H 2017.
GSK 165
Phase 2b data likely due 1Q 2019.
Chronic obstructive pulmonary disease (COPD)
BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017. Advisory Committee Meeting September 13, 2017 voted 11-0 in favor.
Approval announced September 18, 2017.
Chronic obstructive pulmonary disease (COPD)
Approval announced July 21, 2017.
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)

Latest News

  1. GSK's new triple lung drug beats other modern inhalers in study
  2. GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations
  3. FDA OKs Glaxo's inhaler, first one to combine 3 medicines
  4. Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
  5. [$$] Andrew Witty jumps into biotech venture capital
  6. GlaxoSmithKline breathes easier as U.S. approves triple lung drug
  7. Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
  8. U.S. FDA approves GSK's three-in-one drug inhaler for COPD
  9. Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
  10. What Analysts Recommend for Novartis in September 2017
  11. 3 High-Yield Healthcare Stocks
  12. Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
  13. France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus
  14. Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
  15. GSK's three-in-one inhaler gets positive opinion from EU agency
  16. Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD
  17. Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
  18. Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in Patients with Eosinophilic COPD at Risk of Exacerbations
  19. 'Impressed' FDA panel unanimously recommends GSK shingles vaccine
  20. FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over